Which place for bismuth subsalicylate in the treatment of enteric infections?
ORS has led to improved outcome of acute gastroenteritis in both industrialised and developing countries. In both settings there is an increasing demand for active therapy to reduce the duration of diarrhoea and its complications. Persistent diarrhoea is a major consequence of intestinal infections and is responsible for a high number of deaths in poor countries. Bismuth subsalicylate has been used for treatment of acute diarrhoea, with preliminary promising results. In this issue of Acta Paediatrica, a trial with BSS is essential. However the results were marginal and did not justify a mass scale use of BSS, also because of poor cost efficacy rate.
Guarino
A
A
Department of Paediatrics, University Federico II, Naples, Italy. alfguari@unina.it
Bruzzese
E
E
D000208:Acute Disease; D001729:Bismuth / Q000627:therapeutic use*; D002675:Child, Preschool; D003967:Diarrhea / Q000188:drug therapy; D005759:Gastroenteritis / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D009942:Organometallic Compounds / Q000627:therapeutic use*; D015532:Rehydration Solutions / Q000627:therapeutic use*; D012459:Salicylates / Q000627:therapeutic use*
D009942:Organometallic Compounds; D015532:Rehydration Solutions; D012459:Salicylates; C015715:bismuth subsalicylate; D001729:Bismuth